Basilea Pharmaceutica AG (BPMUF)
USD 47.5
(0.0%)
USD 47.5
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 128.6 Million CHF | -31.28% |
| 2022 | 187.13 Million CHF | -14.53% |
| 2021 | 218.95 Million CHF | -9.64% |
| 2020 | 242.31 Million CHF | 22.54% |
| 2019 | 197.74 Million CHF | 0.38% |
| 2018 | 196.98 Million CHF | 0.39% |
| 2017 | 196.22 Million CHF | 0.63% |
| 2016 | 195 Million CHF | 0.0% |
| 2015 | 195 Million CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| 2012 | - CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 112.44 Million CHF | 0.0% |
| 2023 Q1 | 167.71 Million CHF | -10.38% |
| 2023 Q2 | 169.77 Million CHF | 1.23% |
| 2023 Q3 | 126.54 Million CHF | -25.46% |
| 2023 Q4 | 128.6 Million CHF | 1.63% |
| 2023 FY | 128.6 Million CHF | -31.28% |
| 2022 Q1 | 229.18 Million CHF | 4.67% |
| 2022 Q3 | 185.15 Million CHF | -19.96% |
| 2022 Q4 | 187.13 Million CHF | 1.07% |
| 2022 FY | 187.13 Million CHF | -14.53% |
| 2022 Q2 | 231.3 Million CHF | 0.93% |
| 2021 Q3 | 218.05 Million CHF | -5.04% |
| 2021 Q1 | 227.95 Million CHF | -5.93% |
| 2021 FY | 218.95 Million CHF | -9.64% |
| 2021 Q2 | 229.64 Million CHF | 0.74% |
| 2021 Q4 | 218.95 Million CHF | 0.41% |
| 2020 Q3 | 240.56 Million CHF | 20.33% |
| 2020 Q4 | 242.31 Million CHF | 0.73% |
| 2020 Q1 | 199.11 Million CHF | 0.7% |
| 2020 FY | 242.31 Million CHF | 22.54% |
| 2020 Q2 | 199.91 Million CHF | 0.4% |
| 2019 Q2 | 197.35 Million CHF | 0.0% |
| 2019 Q4 | 197.74 Million CHF | -0.28% |
| 2019 Q1 | 197.35 Million CHF | 0.19% |
| 2019 Q3 | 198.28 Million CHF | 0.47% |
| 2019 FY | 197.74 Million CHF | 0.38% |
| 2018 FY | 196.98 Million CHF | 0.39% |
| 2018 Q4 | 196.98 Million CHF | 0.0% |
| 2018 Q3 | 196.98 Million CHF | 0.19% |
| 2018 Q2 | 196.6 Million CHF | 0.0% |
| 2018 Q1 | 196.6 Million CHF | 0.19% |
| 2017 Q2 | 195.84 Million CHF | 0.0% |
| 2017 FY | 196.22 Million CHF | 0.63% |
| 2017 Q4 | 196.22 Million CHF | 0.0% |
| 2017 Q3 | 196.22 Million CHF | 0.2% |
| 2017 Q1 | 195.84 Million CHF | 0.19% |
| 2016 Q3 | 195.46 Million CHF | 0.2% |
| 2016 FY | 195 Million CHF | 0.0% |
| 2016 Q2 | 195.08 Million CHF | 0.0% |
| 2016 Q1 | 195.08 Million CHF | 0.19% |
| 2016 Q4 | 195.46 Million CHF | 0.0% |
| 2015 FY | 195 Million CHF | 0.0% |
| 2015 Q4 | 194.7 Million CHF | 0.0% |
| 2015 Q3 | 194.7 Million CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 Q3 | - CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q1 | - CHF | 0.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2012 Q4 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2012 FY | - CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -6580.831% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -212.128% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -31903.564% |
| SQZ Biotechnologies Company | 27.47 Million USD | -368.152% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -5429.17% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -196.512% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -332.04% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -13462.157% |
| Marizyme, Inc. | 18.71 Million USD | -587.09% |
| Genus plc | 233.1 Million USD | 44.828% |
| Pharming Group N.V. | 171.54 Million USD | 25.031% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -14381.614% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -9471.862% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -17047.467% |
| ContraFect Corporation | 2.88 Million USD | -4363.936% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -8791.953% |
| IMV Inc. | 28.88 Million USD | -345.252% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -2172.852% |
| ONE Bio Corp. | 19.71 Million USD | -552.325% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -123.705% |
| Mesoblast Limited | 118.7 Million USD | -8.345% |
| MultiCell Technologies, Inc. | 202.58 USD | -63483955.682% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -288.526% |
| Genscript Biotech Corporation | 417.73 Million USD | 69.214% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -20311.156% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -10369.723% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -3020.023% |
| Biomind Labs Inc. | 735.54 Thousand USD | -17384.522% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -4149.765% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -889.506% |
| Skye Bioscience, Inc. | 4.61 Million USD | -2686.535% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -35652.69% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -4288.702% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -90776.072% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -94821.284% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -2090.496% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -499942.77% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -8503.841% |
| Q BioMed Inc. | 4.1 Million USD | -3029.114% |
| GB Sciences, Inc. | 1.75 Million USD | -7210.037% |
| Alpha Cognition Inc. | 1.22 Million USD | -10438.262% |
| CSL Limited | 12.18 Billion USD | 98.944% |
| Agentix Corp. | 50 Thousand USD | -257112.0% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -90.125% |
| Enzolytics Inc. | 996.33 Thousand USD | -12807.869% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | -1881.297% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -50216.911% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -5594.61% |
| argenx SE | 20 Million USD | -543.03% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -182.278% |
| HST Global, Inc. | 98.31 Thousand USD | -130704.829% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -51607.141% |
| Halberd Corporation | 150 Thousand USD | -85637.333% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1718.315% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1257660.391% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -4647.881% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -5263.67% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -55988.551% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -86413.649% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -64005.555% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -5746.046% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -532.654% |
| Kadimastem Ltd | 891.22 Thousand USD | -14330.234% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -2629.667% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -51304.977% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -382587.615% |
| Cell Source, Inc. | 9.25 Million USD | -1289.708% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -16906.787% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -16906.787% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -26455.905% |
| Itoco Inc. | 228.37 Thousand USD | -56213.026% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -60857.933% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -2480.895% |
| International Stem Cell Corporation | 4.17 Million USD | -2978.171% |
| CytoDyn Inc. | 30.07 Million USD | -327.603% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -36451.683% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1544.586% |
| SYBLEU INC | 477.5 Thousand USD | -26833.194% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -104884.49% |
| Rebus Holdings, Inc. | 310 Thousand USD | -41385.806% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -2615.91% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -205956.431% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -5796.923% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -1446.489% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -1398.031% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -8167.935% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -47887.313% |
| Neutra Corp. | 54.15 Thousand USD | -237373.225% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -6927.65% |
| PureTech Health plc | 25.51 Million USD | -404.1% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -10405.086% |
| IXICO plc | 472.02 Thousand USD | -27145.706% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -729.663% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -106.553% |
| CSL Limited | 12.18 Billion USD | 98.944% |
| Cellectis S.A. | 92.77 Million USD | -38.619% |